about
Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseSmall Bowel Diverticulosis: An Overlooked Entity.5-ASA Dose-Response: Maximizing Efficacy and Adherence.Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.A new look at a mainstay ulcerative colitis therapyOsteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment.Fulminant Colitis Following Rituximab Therapy.How Relative Value Units Undervalue the Cognitive Physician Visit: A Focus on Inflammatory Bowel Disease.Small bowel adenocarcinoma in Crohn's disease.Therapeutic Use of Cannabis in Inflammatory Bowel Disease.Screening and diagnosis of prostate cancer in patients with ileal pouch-anal anastomosis: consensus from an expert panel.Inflammatory bowel disease of the elderly: frequently asked questions (FAQs).Management of the elderly patients with inflammatory bowel disease: practical considerations.Management of inflammatory bowel disease in the elderly: do biologicals offer a better alternative?Endoscopy in the elderly: risks, benefits, and yield of common endoscopic procedures.Clinical implications of ageing for the management of IBD.Smoking and early infliximab response in Crohn’s disease: a meta-analysis.Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis.Crohn's disease and colorectal carcinoma: rectal cancer complicating longstanding active perianal disease.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.Chronic appendicitis: uncommon cause of chronic abdominal pain.Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF.Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.My treatment approach to the management of ulcerative colitis.Keys to success with clinical trials.MMX mesalamine is safe and efficacious in achieving clinical and endoscopic remission of active ulcerative colitis.Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.Elderly-onset IBD: a milder disease?Variation at NOD2/CARD15 in familial and sporadic cases of Crohn's disease in the Ashkenazi Jewish population.Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease.Update on Relative Value Units and the Cognitive Physician Visit.Site organization and management.Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.Recurrent free perforation in gastroduodenal Crohn's disease.Massive pyoderma gangrenosum in a 77 year old female with Crohn's disease responsive to adalimumab.
P50
Q30054715-481CB5A5-5B27-43F6-8C87-B22DEF950C2DQ33426288-74A9CB2A-DDC9-4CBF-8E67-EDA703C4C026Q33916329-8F47481A-2C03-4579-B5A5-3D13E9FDC360Q34598488-8307E34C-C3AF-4306-82DB-781FD08F25DDQ34805216-D5C63267-A9FA-41B4-BE4A-8308130ACCB2Q34940520-8EE9B448-D9A5-4146-ABA6-120EF275C091Q36478209-2385E934-C131-43AB-B6B0-8797F9C59E7CQ36897788-F5FE1F45-9CFC-498E-BB57-3805872E30EBQ36916663-4D092853-3BCF-4B53-A61C-132A76FB3DEAQ37084760-92354307-0D7C-4F03-9FCF-2CC6C2E7D4F8Q37540208-64F50BF9-1B2F-47E1-ACD7-7C97983663F5Q37837466-179C2289-9D2D-46B3-A247-ED5518773FA6Q37921606-3A322A8C-08C3-4652-8F1E-44712272C86FQ38122069-F10C3E42-DDBD-4F59-8D12-2EB327BCD548Q38141975-57E8327D-6E33-4BED-8A52-0E23A837FBC7Q38165421-5EB1FEAD-AF40-4057-87FD-B421B5D57C8DQ38171926-DACB0567-8B02-4ECA-AE4C-BCD9B74AFBB0Q38291955-AA6E8340-60AE-466B-972A-CEEDAB488F54Q38357630-A2CEA02D-95BD-46FC-96C6-88503BF880DEQ38572084-ACBEBC8D-8D55-4821-A45E-5922B5C77DD7Q38973323-28620D5B-C2AD-4B43-B664-00BAED22545DQ39194640-751AD116-48D8-4A84-8253-DB0E41B84154Q40146462-FD3E766C-6A54-4D60-8669-85754ADD0640Q40655110-937E6239-C585-407A-A7B5-F48CDD2566C3Q40667799-47B795AB-E43A-444A-88A3-62E13D5A750DQ42199158-9333E00F-E721-4DA5-8269-DB5CECD12D8FQ42252716-94012566-20F6-4356-8E7A-7A74D4DD2959Q42701058-F8BA63C6-66B0-48A2-88D6-530CEEC81F38Q42874557-DCD0E29C-5C50-47B2-912B-94F8F9C2BC57Q44042865-64C35082-8041-48EF-BD30-47C8E8FDA2C0Q44488021-9ECA2F61-B495-4191-BD52-5845D2AD361EQ44662725-717A8754-5EF1-423D-9717-CD79CDC5C3D8Q45207573-ECE74603-E50E-4E3A-A72C-1E0ED61CC3FBQ50055464-1917CA17-EB88-41A1-8E86-6130E695046CQ50102071-C66B7607-609C-4EB7-A38B-B1D45C859795Q50318606-283BF935-85C2-4043-B364-99BB7C625655Q50954004-CED42BCD-E882-486A-B9DA-DF09A7071038Q51167471-4DBC53C9-747F-480D-9644-9948E045747DQ51239155-7F694F00-7DC9-40A8-A9C3-6EB9A7EBB3EFQ51315372-A4A35F1D-BBFD-49F1-AFA5-511ECAE9BF71
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Seymour Katz
@ast
Seymour Katz
@en
Seymour Katz
@es
Seymour Katz
@nl
type
label
Seymour Katz
@ast
Seymour Katz
@en
Seymour Katz
@es
Seymour Katz
@nl
altLabel
Katz S
@en
prefLabel
Seymour Katz
@ast
Seymour Katz
@en
Seymour Katz
@es
Seymour Katz
@nl
P214
P106
P214
P31
P4012
P496
0000-0002-3492-9200
P7859
viaf-163960682